

Radiotherapy Considerations for Nasopharyngeal Carcinoma

Subjects: Oncology

Contributor: Wai Tong Ng, James C.H. Chow, Jonathan J. Beitler, June Corry, William Mendenhall, Anne W. M. Lee, Kevin Robbins, Sandra Nuyts, Nabil Saba, Robert Smee, William A. Stokes, Primož Strojan, Alfio Ferlito

Radiotherapy is the primary treatment modality for nasopharyngeal carcinoma (NPC). Successful curative treatment requires optimal radiotherapy planning and precise beam delivery that maximizes locoregional control while minimizing treatment-related side effects.

Keywords: nasopharyngeal cancer ; radiotherapy ; target delineation ; adaptive planning

1. Introduction

Radiotherapy is the key treatment modality for nasopharyngeal carcinoma (NPC). With the advent of intensity-modulated radiotherapy (IMRT) and refinements to different imaging modalities, the precision of radiation delivery has significantly improved in the recent decade, giving rise to favorable tumor control and toxicity outcomes in contemporary cohorts ^{[1][2]}. International consensus guidelines have emerged to harmonize variations in tumor target delineation and to guide dose prioritization for NPC radiotherapy ^{[3][4]}. Since then, researchers have been active in further optimizing the therapeutic ratio by refining the delineation of tumor targets and organs at risk (OAR) and personalizing radiation prescription doses.

2. Target Delineation

Target delineation in radiotherapy for NPC is highly challenging given the complex local anatomy, tumor spreading pattern, and the intricate relationship between tumor targets and multiple critical OAR. An accurate, cautious, and rational target delineation process is crucial to attaining satisfactory loco-regional control and long-term cure. Special efforts are also required in the proactive sparing of normal structures to minimize the incidence and severity of radiation-associated complications, many of which may pose lifelong detriments to the quality of life of survivors.

With the advent of high-resolution fiberoptic endoscopy, magnetic resonance imaging (MRI), and positron emission tomography (PET), the accuracy of the gross tumor volume (GTV) delineation for both primary nasopharyngeal tumors and regional lymph nodes has greatly improved. Input from diagnostic radiologists specializing in head and neck cancers is of vital importance in ensuring the accurate interpretation of all pre-treatment staging images. The challenge for radiation oncologists now resides in determining the optimal extents of high- and low-risk clinical target volumes (CTV), which could vary significantly depending on the presenting stage of disease as well as institutional practices and consensus guidelines ^{[4][5]}. Regular quality assurance programs and peer reviews also play an essential role in ensuring correct target delineation and satisfactory dosimetry ^[6].

Traditionally, CTV delineation for NPC has relied on historical studies which reported the natural route of spread with the aim of prophylactically treating areas that were included within the radiation portals used in the era of two-dimensional radiotherapy. In 2018, a set of international consensus guidelines were published to instruct CTV delineation for NPC ^[4]. They defined high-risk CTV (CTV1) as a 5 mm volumetric expansion from GTV, whereas low-risk CTV (CTV2) includes a further 5 mm expansion from CTV1. These CTVs were then manually edited to cover specific anatomical regions according to the eccentric local spread pattern with the exclusion of natural barriers. For gross tumors encroaching onto critical neurological structures at risk, a tighter CTV margin of 1–2 mm was recommended as a necessary trade-off to balance tumor control and the risk of complications.

It is noted that while CTV delineation based on “5 + 5” expansion margins and anatomic landmarks represents a one-size-fits-all approach that prioritizes tumor coverage, the final treatment volumes tend to be larger, potentially leading to a higher risk of acute and late complications. Given the growing understanding of failure patterns and the increasing

awareness of survivorship issues in NPC patients, there have been ongoing efforts to individualize CTV delineation according to various tumor extents.

2.1. CTV Delineation of Primary Tumors

The intricate anatomy immediately surrounding the nasopharynx requires the precise delineation of gross primary tumors and corresponding target volumes. A multimodal imaging approach including contrast-enhanced computer tomography, gadolinium-enhanced magnetic resonance imaging (MRI), and ¹⁸F-fluorodeoxyglucose positron emission tomography (PET) offers the most comprehensive anatomic depiction of tumor extent. These diagnostic studies can be imported into radiation treatment planning systems and registered with simulation scans to facilitate contouring target volumes.

The international CTV delineation guidelines recommended the symmetrical inclusion of structures at risk of microscopic spread regardless of the laterality of the primary tumor [4]. One area of active research is the selected sparing of the contralateral structures in patients presenting with unilateral disease. As the fossa of Rosenmüller is the most common site of origin, early NPC typically presents unilaterally and may remain so as the tumor advances, constituting approximately 10% of all NPC at presentation [7][8]. An endoscopic biopsy study has revealed a low incidence of occult microscopic disease in the contralateral nasopharyngeal mucosa in unilateral NPC which did not cross the midline [7]. The risk of skipped discontinuous invasion to the contralateral parapharyngeal space and skull base is also exceedingly low in unilateral NPC, making unilateral irradiation an attractive option to reduce radiation side effects, such as trismus and xerostomia [9].

In a retrospective report of 95 unilateral NPC, unilateral irradiation was delivered by delineating CTV2 as a 15–20 mm volumetric expansion from GTV with deliberate exclusion of contralateral nasopharyngeal mucosa and parapharyngeal space and skull base structures [10]. This contouring approach has led to an excellent 10-year local recurrence-free survival rate of 96.2%, in which no out-field recurrence occurred contralaterally. Importantly, mean radiation doses to the contralateral organs at risk, such as the parotid, middle ear, and temporomandibular joint, were 13–33% lower than those of their ipsilateral counterparts, and no significant late toxicity was reported. In another study, Sanford et al. reported the clinical outcomes of 73 patients who were treated using a CTV delineation method individualized to the primary tumor extent [11]. Apart from limiting CTV2 to the ipsilateral parapharyngeal space, pterygopalatine fossa, and foramen ovale in lateralized tumors, there was no routine inclusion of the clivus, nasal cavity, maxillary sinus, ethmoid sinus, or sphenoid sinus unless these structures were involved. Compared to the standard contouring protocol in the NRG HN001 trial, this target delineation approach resulted in a 36–62% reduction in CTV2 volume and radiation doses to multiple normal structures. The 5-year local control rate was high at 94% and all loco-regional recurrences occurred within the high-dose CTV.

Another area of active research is the reduction in CTV upon response to induction chemotherapy. In recent years, there has been increasing evidence to support the adoption of extended chemotherapy in advanced NPC, demonstrating significant improvement in both recurrence-free survival and overall survival compared to chemo-radiotherapy alone [12][13]. Traditionally, with the concern that tumor regression after chemotherapy is not uniformly eccentric, the conventional practice was to treat all pre-chemotherapy gross tumors to a full therapeutic radiation dose of at least 70 Gy [4]. However, this approach often results in large treatment volumes with potentially unnecessary toxicities. Retrospective evidence in T4 NPC supports the feasibility and safety of restricting the 70 Gy volume to the post-chemotherapy disease extent while treating the pre-chemotherapy extent with 60 Gy, after which no out-field local failure was reported [14]. A similar approach has been reported in a phase II de-escalation trial, with part of the post-chemotherapy GTV receiving a moderate dose reduction of 66 Gy for T3–4 diseases [15]. This adaptive CTV delineation approach was also tested in a phase III randomized controlled trial [16]. In the experimental arm of this trial, CTV1 (64 Gy; GTV boosted to 70 Gy) covered a 0.5–1 cm margin from the post-chemotherapy tumor, and CTV2 (54 Gy) covered all at-risk regions plus the pre-chemotherapy tumor extent. Compared with conventional contouring, this approach markedly reduced the mean volume of CTV1 from 366 cc to 305 cc. Patients who were treated with adaptive target delineation had a 2-year overall survival comparable to controls, but with a lower incidence of dry mouth and better quality of life metrics. The results of a recent prospective phase II study also confirmed long-term efficacy with this approach and reported no out-field local recurrence at a median follow-up of 10 years [17]. It is noted that all of the above studies treated skull base disease according to the pre-chemotherapy extent as the tumor response in bony structures is challenging to ascertain.

2.2. CTV Delineation of Regional Lymphatics

NPC has a high propensity for nodal metastasis, with more than 50% of patients presenting with advanced nodal disease [1]. In a meta-analysis of patients totaling 2920 NPC cases who were staged using MRI, 85% were found to have lymphadenopathy, among whom 69% had retropharyngeal nodes and 70% had nodal disease in level II [18]. In this

context, the close proximity of the retropharyngeal nodal basin to the nasopharynx deserves special consideration. These lymph nodes lie within a fat pad located behind the posterior wall of the oropharynx and nasopharynx. Behind them lies the prevertebral fascia. The nodes can extend caudal from the skull base to the level of the carotid bifurcation. The medial retropharyngeal nodes lie in the midline at a level between the first and fourth cervical vertebrae, whereas the lateral nodes are located immediately medial to the internal carotid artery. The nodes are supplied by afferent lymphatics from the nasal cavity, nasopharynx, and eustachian tubes [19]. Their primary efferent channels extend towards the deep cervical nodes that lie along the internal jugular vein in level II. Lin et al. evaluated 1000 NPC patients for nodal disease involving selected levels [20]. In a total of 10,651 nodes imaged, there were 819 nodes detected in the newly classified level VIIA, and 5 of them involved the medial retropharyngeal nodes.

Prior to imaging techniques that adequately depicted the medial and lateral retropharyngeal lymph nodes, it was common understanding that lymph nodes in level II were the most common sites for clinical metastases from NPC. Although the French anatomist Henri Rouvière documented the retropharyngeal lymphatics through anatomical dissections, there remained insufficient evidence to depict retropharyngeal nodal metastases clinically unless they were markedly enlarged. Since the advent of CT, MRI, and FDG-PET scans, retropharyngeal node involvement with NPC is more commonly appreciated. Consequently, the retropharyngeal lymphatics with their nodal basin, both medial and lateral, have become recognized as the primary echelon for lymphatic drainage from the nasopharynx. However, level II may also be the first echelon lymphatic basin without retropharyngeal node involvement, especially for primary diseases that extend laterally.

The lymphatic spread of NPC typically follows a stepwise pattern, starting from the upper basins, including the retropharyngeal and level II nodes, and then extending caudally along the deep cervical (jugular) and spinal accessory nodes. Ho FC et al. showed that the percentage of patients with positive nodal involvement in levels III, IV, and V was determined to be 45%, 11%, and 27%, respectively. Among low-risk nodal basins were the supraclavicular nodes, level I, level VI, and the parotid gland, all of which varied from 0% to 3%. The authors reported that the probability of skip metastasis between levels varied between 0.5 and 7.9%, leading to the suggestion that a reduced treatment volume for the elective irradiation of subclinical NPC nodal disease is feasible [18].

Toward a more refined approach for reduced treatment volume based on the risks of occult nodal disease, CTV delineations have become based on the international consensus agreement in 2013 intended to minimize inter-observer variation in nodal delineation for head and neck cancers [21]. Since then, researchers have tried to further refine the delineation boundaries according to the unique nodal spread pattern of NPC. In one study which investigated the distribution of 10,665 involved cervical nodes of patients with NPC, it was shown that the consensus atlas missed 13% of the nodes posteromedial to the level Vb boundaries and 1.5% of the nodes cranial to the level VIIa boundaries [21]. By contrast, no cervical node involvement was identified in the following specific areas: within the submandibular gland; the gap between the sternocleidomastoid and splenius muscles in level II; the gap between the sternocleidomastoid and infrahyoid muscles in level IVa; and the gap between the skin and omohyoid muscle in level Vc. Therefore, the NPC-specific delineation of the cervical lymphatics was proposed to improve coverage and reduce unnecessary normal tissue irradiation, which contributes to neck fibrosis and post-radiation hypothyroidism [22].

The conventional delineation of level Ib includes the entire submandibular gland and a larger area of soft tissue between the oral cavity and the mandible, the irradiation of which leads to substantial salivary dysfunction and long-term oral complications. The current guidelines recommend limiting the prophylactic irradiation of level Ib nodal basins only when tumors invade the submandibular gland, oral cavity or nasal cavity, and in situations where level IIa nodes are large or demonstrate features of extracapsular extension [4]. Modifications of the level Ib nodal CTV boundaries have been specifically proposed for NPC. In one nodal topographic study of 54 NPC patients with positive level Ib nodes, researchers reported a very low risk of nodal occurrence within and medial to the submandibular glands, whereas most radiologically abnormal nodes were found eccentrically above or below the glands [23]. By limiting the elective level Ib boundaries to the soft tissues within specific distances (11 mm superiorly and 17 mm inferiorly) but not intentionally targeting the submandibular glands, radiation volumes could be significantly reduced compared to those when using the standard consensus atlas, which may attenuate the excess dose to the salivary glands, mandible, and the oral cavity mucosa.

International consensus guidelines have recommended the prophylactic irradiation of level Ib nodal basins when level II nodes are sizable (>2 cm) or exhibit radiological evidence of extracapsular extension. Recently, a large propensity score-matched analysis evaluated the feasibility of sparing level Ib nodal basins in these traditionally high-risk scenarios. It was shown that the rate of level Ib failure remained exceptionally low (1.8%), and its omission could lead to a lower incidence of xerostomia [24]. These new data support a more stringent selection of patients for prophylactic level Ib irradiation, prompting a potential revision of the current target delineation guidelines.

3. Optimizing Prescription Doses

3.1. Dose De-Escalation

Concerning the prescription dose of definitive radiotherapy for NPC, most head and neck oncologists practice in accordance with international consensus guidelines by giving a dose of 70 Gy to high-risk CTV and 50–60 Gy to low- to intermediate-risk CTV [4]. Treatment is typically delivered using the simultaneous integrated boost technique with different radiation doses delivered to target volumes within a single treatment fraction. With contemporary imaging modalities, such as MRI and PET, the definition of tumor extent and sensitivity in detecting pathologic nodes have significantly improved, leading to the proposal of a “gradient-dose” concept in dose prescription for head and neck squamous cell carcinomas [25] [26]. Instead of the conventional binary two-tier CTV system, this concept advocates the focus of high-dose radiotherapy only on gross tumors identified by contemporary imaging along with the delivery of a decreasing radiation dose over a defined distance from the main disease, thereby reducing radiation toxicity.

Similar radiation dose prescription approaches have long been practiced by multiple oncology centers for NPC in China. The full therapeutic radiation dose of 70 Gy was limited to the GTV with no additional CTV margin, followed by 60 Gy and 50–54 Gy for intermediate-risk and low-risk CTV, respectively [5]. In one prospective observational study of 471 patients, by restricting the radiation dose of 66–70 Gy to GTV and 54–56 Gy to CTV (8 mm isocentric expansion from GTV) with an additional 3 mm planning target volume margin on each volume, an excellent 4-year local recurrence-free survival rate of 96.6% was reported with no in-field failure [27]. Compared to the prescription recommendations in the international guidelines, this de-escalated prescription approach restricts the zone of high-dose radiation, potentially reducing radiotherapy complications in NPC patients while apparently maintaining oncologic safety.

The next key question is whether a high radiation dose of 70 Gy is necessary to attain a cure for all NPC. A retrospective propensity score-matched analysis on a small series of 32 T1–T3 NPC patients with incomplete radiotherapy at doses of 53–67.8 Gy reported comparable 5-year loco-regional relapse-free survival with patients who received the full 70 Gy (92.5% vs. 91.7%) [28]. Albeit retrospective, this evidence suggested that the uniform conventional dose prescription may not be necessary for radiosensitive tumors such as NPC. In the same vein, a logical approach by which to attempt dose de-escalation is to focus on tumors that demonstrate favorable responses to induction chemotherapy. Clinical trials of pediatric NPC have reported a satisfactory 5-year event-free survival rate of 77–91% with 45–68 Gy of radiotherapy following induction chemotherapy, and the dose could be safely reduced from 59.4 Gy to 54.4 Gy for patients who attained complete remission on MRI and PET [29][30]. Comparable survival outcomes between dose-reduced (60–65.9 Gy) and standard-dose (66–72 Gy) IMRT following favorable responses to induction chemotherapy have also been reported in a recent pediatric NPC study [31]. Furthermore, in a phase II clinical trial from China, 216 adult patients with stage III NPC who had low pre-treatment Epstein–Barr virus (EBV) DNA levels (<4000 copies/mL) were treated with 60 Gy of radiotherapy after a complete or partial response to induction chemotherapy [32]. This approach yielded an encouraging 2-year loco-regional recurrence-free survival rate of 95% without high-grade late toxicity. Future prospective comparative evidence is important to ascertain the safety of dose de-escalation with regard to the current standard of 70 Gy.

3.2. Dose Escalation

Despite the significant improvement in loco-regional control with modern chemo-radiotherapy, dosimetric analyses have indicated that most local recurrences of NPC occurred within the high-dose CTV which received a full therapeutic dose of radiation [33]. This observation prompted interest in radiation dose escalation in selected tumors to improve loco-regional control further.

Several dose-escalation studies in NPC have reported encouraging treatment outcomes. These studies used standard anatomical imaging for target delineation and adopted a simultaneous integrated boost technique to treat the gross tumor. With regard to the GTV, these escalated regimens were typically hypofractionated at 2.17–2.42 Gy per fraction, prescribed at total nominal radiation doses of 66–76 Gy [33][34][35][36][37]. The reported short-term loco-regional control rates were high at 87–91%, yet no comparative studies were available to inform a clear benefit over standard non-escalated regimens. In addition, long-term toxicity data were unavailable due to inconsistent reporting and limited follow-up durations.

Instead of dose escalating the whole anatomically defined tumors, recent research has focused on the targeted image-guided dose painting of functionally active or radio-resistant areas. In a small randomized control trial which utilized ¹⁸F-PET as functional pre-treatment imaging, locally advanced NPC was treated by boosting areas with a standardized uptake value (SUV) ≥ 2.5 to 77Gy in 32 fractions [38]. The 3-year disease-free survival rate of 95.2% with this approach was superior to the rate of 79.2% obtained with conventional radiotherapy, providing preliminary evidence to support radiation dose escalation directed by functional imaging. Subsequently, in an observational study, ¹⁸F-PET was used to

dose escalate radiotherapy for 101 loco-regionally advanced NPC [39]. By treating the GTV with 70.4–72.6 Gy in 33 fractions and boosting the sub-volume of gross tumors with $\geq 50\%$ of the maximum SUV with 75.2–77.6 Gy, the 3-year disease-free survival rate was higher than that of the non-escalated control (87.9% vs. 82.4%), and there was no reported increase in high-grade adverse events.

Diffusion-weighted (DW) sequences from MRI have also been utilized to guide radiation dose escalation in NPC. A low apparent diffusion coefficient (ADC) value in DW-MRI is associated with adverse treatment outcomes independent of clinical stage and other known prognostic factors [40]. A recent randomized controlled trial of 260 patients reported improved disease-free survival with DW-MRI-guided dose-painting IMRT in loco-regionally advanced NPC compared with that of standard IMRT [41]. Following induction chemotherapy, patients in the experimental arm of this trial received 70.4–72.6 Gy in 32–33 fractions to GTV with an additional concomitant boost of 75.2–77.6 Gy to tumor areas with ADC below the mean value in the pre-induction images. This functional MRI-guided IMRT led to significant improvement in all survival endpoints with an excellent 2-year local recurrence-free survival rate of 100%. No significant increase in acute or late adverse events was reported.

It is noted that the comparable reported rates of radiation toxicities between dose-escalated and conventional IMRT should be viewed with caution, as the median follow-up durations of these studies were short at 2–3 years, within which radiation late effects are yet to manifest [42]. In addition, the lists of reported late complications in these studies were in many cases incomplete and non-exhaustive. Currently, the optimal SUV or ADC cut-offs to define boost volumes remain unclear, and the spatial and temporal variations of these metrics within tumors are also poorly characterized [43]. Further data, in particular 5- to 10-year survival rates, are required to inform practice as well as long-term safety with these dose-escalation approaches.

4. Sparing Organs at Risk

The introduction of IMRT as the standard radiotherapy technique for NPC has not only improved disease control, but has also reduced inadvertent radiation to multiple critical organs. The typical OARs of interest include the brainstem, spinal cord, optic structures, temporal lobes, auditory apparatus, pharyngeal constrictors, esophagus, larynx, oral cavity, salivary glands, pituitary gland, thyroid, and mandible [3][44]. Evidence from randomized controlled trials has demonstrated lower rates of physician-rated xerostomia and a superior preservation of salivary flow with IMRT than with 2D radiotherapy [45][46]. Incidences of multiple other late toxicities, such as temporal lobe necrosis, cranial nerve palsy, trismus, and neck fibrosis, were also reduced [47]. With the increasing awareness of late radiation complications and advances in radiotherapy dose optimization, researchers have strived to further reduce incidental radiation dose to specific OARs in NPC.

Post-radiation hearing deficit significantly impairs the quality of life of NPC survivors. The risk of hearing impairment after chemo-radiotherapy varies as a function of the pre-treatment status of auditory apparatus, radiation dose to the cochlea, and cumulative cisplatin dose. Given the current paradigm of intensive chemotherapy for localized NPC, the maximal prescribed cisplatin dose of 480–540 mg/m² for patients with advanced diseases commonly reaches ototoxic levels [12][13]. It has therefore become prudent to enforce the superior protection of the auditory apparatus during radiotherapy planning. The QUANTEC and international guidelines have recommended that the mean cochlea dose be desirably kept below 45 Gy [3][48]. However, this threshold should not be viewed as risk-free, as the hearing impairment rate is still up to 30% for plans in which this criterion is fulfilled [49]. To achieve better cochlea-sparing, special optimization procedures with volumetric arc therapy may be considered [50][51][52]. By combining jaw closure, jaw tracking, a modification of the beam angle and a reordering of structure priority, mean cochlea doses could be significantly reduced as opposed to conventional planning without compromising PTV coverage, even in situations of advanced tumors with gross invasion to the petrous bone. These planning approaches, when used in combination, have been shown to reduce the mean cochlea dose by approximately 4–6 Gy. As the cochlea dose in NPC radiotherapy plans commonly falls at 40–50 Gy, where the slope of the normal tissue complication probability (NTCP) curve is steepest, even a slight decrease in the cochlea dose could result in a clinically meaningful reduction in the incidence of post-radiation hearing impairment. Furthermore, adopting volumetric arc therapy may also improve the dosimetric sparing of other OARs, such as the parotid gland, brainstem, and spinal cord, compared with step-and-shoot IMRT [53][54].

Radiation-induced cranial neuropathy in NPC survivors is another commonly overlooked late complication which can lead to a permanent detriment in speech and swallowing dysfunction in NPC survivors. In contemporary reports, the rate of long-term cranial nerve palsy in NPC survivors is as high as 5% with the hypoglossal nerve being one of the most commonly injured structures [1][55][56]. Traditionally, apart from the optic nerves, other cranial nerves are considered radio-resistant, and no special attempts have been made to protect them during radiotherapy planning. In a recent retrospective

study, the maximal dose received by 1 cc volume (D1cc) of the hypoglossal nerve was found to be predictive of the risk of post-radiation hypoglossal nerve palsy in NPC survivors [57]. Hypoglossal nerve D1cc \geq 74 Gy was associated with a high risk of future palsy (8-year; D1cc \geq 74 Gy, 20.8%; D1cc $<$ 74 Gy, 2.4%). By applying a dedicated dose constraint to remove hotspots within the hypoglossal nerves, neither the tumor target coverage nor dosimetric safety of other standard critical organs was compromised [58]. Its application should be routinely considered for NPC radiotherapy planning especially when dose escalation to the primary nasopharyngeal tumor is contemplated.

References

1. Au, K.H.; Ngan, R.K.C.; Ng, A.W.Y.; Poon, D.M.C.; Ng, W.T.; Yuen, K.T.; Lee, V.H.F.; Tung, S.Y.; Chan, A.T.C.; Sze, H. C.K.; et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IM RT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). *Oral Oncol.* 2018, 77, 16–21.
2. Liang, S.-B.; Wang, Y.; Chun-Yan, C.; He, S.-S.; Yang, X.-L.; Liu, L.-Z.; Cui, C.-Y.; Chen, Y.; Fu, L.-W. Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China. *J. Cancer* 2017, 8, 3718–3724.
3. Lee, A.W.; Ng, W.T.; Pan, J.J.; Chiang, C.-L.; Poh, S.S.; Choi, H.C.; Ahn, Y.C.; AlHussain, H.; Corry, J.; Grau, C.; et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* 2019, 105, 567–580.
4. Lee, A.W.; Ng, W.T.; Pan, J.J.; Poh, S.S.; Ahn, Y.C.; AlHussain, H.; Corry, J.; Grau, C.; Grégoire, V.; Harrington, K.J.; et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. *Radiation Therapy Oncology* 2018, 126, 25–36.
5. Zhang, S.; Yang, S.; Xu, P.; Xu, Y.; Zhou, G.; Ou, X.; Wu, R.; Lan, M.; Fontanarosa, D.; Dowling, J.; et al. Variations of Clinical Target Volume Delineation for Primary Site of Nasopharyngeal Cancer Among Five Centers in China. *Front. Oncol.* 2020, 10, 1572.
6. Corry, J.; Ng, W.T.; Moore, A.; Choi, H.C.; Le, Q.; Holmes, S.; Munandar, A.; Wang, S.; Camacho, A.; Setakornnukul, J.; et al. Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. *Int. J. Radiat. Oncol.* 2021, 111, 1227–1236.
7. Li, A.-C.; Zhang, Y.-Y.; Zhang, C.; Wang, D.-S.; Xu, B.-H. Pathologic study of tumour extension for clinically localized unilateral nasopharyngeal carcinoma: Should the contralateral side be included in the clinical target volume? *J. Med. Imaging Radiat. Oncol.* 2018, 62, 540–547.
8. Sun, Y.; Yu, X.-L.; Zhang, G.-S.; Liu, Y.-M.; Tao, C.-J.; Guo, R.; Tang, L.-L.; Zhang, R.; Guo, Y.; Ma, J. Reduction of clinical target volume in patients with lateralized cancer of the nasopharynx and without contralateral lymph node metastasis receiving intensity-modulated radiotherapy. *Head Neck* 2016, 38 (Suppl. 1), E468–E472.
9. Wu, Z.; Zhang, L.; He, Q.; Li, F.; Ma, H.; Zhou, Y.; Wang, H.; Han, Y. Characteristics of locoregional extension of unilateral nasopharyngeal carcinoma and suggestions for clinical target volume delineation. *Radiat. Oncol.* 2022, 17, 52.
10. Xie, D.-H.; Wu, Z.; Li, W.-Z.; Cheng, W.-Q.; Tao, Y.-L.; Wang, L.; Lv, S.-W.; Lin, F.-F.; Cui, N.-J.; Zhao, C.; et al. Individualized clinical target volume delineation and efficacy analysis in unilateral nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT): 10-year summary. *J. Cancer Res. Clin. Oncol.* 2022, 148, 1931–1942.
11. Sanford, N.N.; Lau, J.; Lam, M.B.; Juliano, A.F.; Adams, J.A.; Goldberg, S.I.; Lu, H.-M.; Lu, Y.C.; Liebsch, N.J.; Curtin, H.D.; et al. Individualization of Clinical Target Volume Delineation Based on Stepwise Spread of Nasopharyngeal Carcinoma: Outcome of More Than a Decade of Clinical Experience. *Int. J. Radiat. Oncol. Biol. Phys.* 2019, 103, 654–668.
12. Sun, Y.; Li, W.-F.; Chen, N.-Y.; Zhang, N.; Hu, G.-Q.; Xie, F.-Y.; Sun, Y.; Chen, X.-Z.; Li, J.-G.; Zhu, X.-D.; et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. *Lancet Oncol.* 2016, 17, 1509–1520.
13. Zhang, Y.; Chen, L.; Hu, G.-Q.; Zhang, N.; Zhu, X.-D.; Yang, K.-Y.; Jin, F.; Shi, M.; Chen, Y.P.; Hu, W.-H.; et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. *N. Engl. J. Med.* 2019, 381, 1124–1135.
14. Kong, F.-F.; Ni, M.-S.; Zhai, R.-P.; Ying, H.-M.; Hu, C.-S. Local control and failure patterns after intensity modulated radiotherapy with reduced target volume delineation after induction chemotherapy for patients with T4 nasopharyngeal carcinoma. *Transl. Oncol.* 2022, 16, 101324.
15. Xue, F.; Ou, D.; Ou, X.; Zhou, X.; Hu, C.; He, X. Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma. *Oral Oncol.* 2022, 134, 106139.

16. Yang, H.; Chen, X.; Lin, S.; Rong, J.; Yang, M.; Wen, Q.; Shang, C.; He, L.; Ren, P.; Xu, S.; et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. *Radiother. Oncol.* 2018, 126, 37–42.
17. Zhao, C.; Miao, J.-J.; Hua, Y.-J.; Wang, L.; Han, F.; Lu, L.-X.; Xiao, W.-W.; Wu, H.-J.; Zhu, M.-Y.; Huang, S.-M.; et al. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study. *Int. J. Radiat. Oncol. Biol. Phys.* 2019, 104, 836–844.
18. Ho, F.C.H.; Tham, I.W.K.; Earnest, A.; Lee, K.M.; Lu, J.J. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: A meta-analysis of clinical evidence. *BMC Cancer* 2012, 12, 98.
19. Pan, W.-R.; Suami, H.; Corlett, R.J.; Ashton, M.W. Lymphatic drainage of the nasal fossae and nasopharynx: Preliminary anatomical and radiological study with clinical implications. *Head Neck J. Sci. Spec. Head Neck* 2009, 31, 52–57.
20. Lin, L.; Lu, Y.; Wang, X.-J.; Chen, H.; Yu, S.; Tian, J.; Zhou, G.-Q.; Zhang, L.-L.; Qi, Z.-Y.; Hu, J.; et al. Delineation of Neck Clinical Target Volume Specific to Nasopharyngeal Carcinoma Based on Lymph Node Distribution and the International Consensus Guidelines. *Int. J. Radiat. Oncol. Biol. Phys.* 2018, 100, 891–902.
21. Grégoire, V.; Ang, K.; Budach, W.; Grau, C.; Hamoir, M.; Langendijk, J.A.; Lee, A.; Le, Q.-T.; Maingon, P.; Nutting, C.; et al. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCI CTG, NCRI, RTOG, TROG consensus guidelines. *Radiother. Oncol.* 2014, 110, 172–181.
22. Ng, W.T.; Ms, R.K.Y.T.; Beitler, J.J.; Bree, R.; Coca-Pelaz, A.; Eisbruch, A.; Guntinas-Lichius, O.; Lee, A.W.M.; Mäkitie, A.A.; Mendenhall, W.M.; et al. Contemporary management of the neck in nasopharyngeal carcinoma. *Head Neck* 2021, 43, 1949–1963.
23. Zhao, Y.; Liao, X.; Wang, Y.; Lan, W.; Ren, J.; Yang, N.; Li, C.; Lang, J.; Zhang, S. Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy. *Radiother. Oncol.* 2022, 172, 10–17.
24. Wang, G.; Huang, C.; Yang, K.; Guo, R.; Qiu, Y.; Li, W.; Mao, Y.; Tang, L.; Ma, J. Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study. *Radiother. Oncol.* 2022; in press.
25. Kaanders, J.H.; Bosch, S.V.D.; Dijkema, T.; Al-Mamgani, A.; Raaijmakers, C.P.; Vogel, W.V. Advances in cancer imaging require renewed radiotherapy dose and target volume concepts. *Radiother. Oncol.* 2020, 148, 140–142.
26. Bosch, S.V.D.; Vogel, W.V.; Raaijmakers, C.P.; Dijkema, T.; Terhaard, C.H.; Al-Mamgani, A.; Kaanders, J.H. Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation. *Radiother. Oncol.* 2018, 128, 472–478.
27. Guo, Q.; Zheng, Y.; Lin, J.; Xu, Y.; Hu, C.; Zong, J.; Lu, T.; Xu, H.; Chen, B.; Liang, Q.; et al. Modified reduced-volume intensity-modulated radiation therapy in non-metastatic nasopharyngeal carcinoma: A prospective observation series. *Radiother. Oncol.* 2021, 156, 251–257.
28. Wang, X.; Wang, Y.; Jiang, S.; Zhao, J.; Wang, P.; Zhang, X.; Wang, F.; Yin, Z.; Wang, P. Safety and Effectiveness of De-escalated Radiation Dose in T1-3 Nasopharyngeal Carcinoma: A Propensity Matched Analysis. *J. Cancer* 2019, 10, 5057–5064.
29. Buehrlen, M.; Zwaan, C.M.; Grenzen, B.; Lassay, L.; Deutz, P.; Vorwerk, P.; Staatz, G.; Gademann, G.; Christiansen, H.; Oldenburger, F.; et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: Preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. *Cancer* 2012, 118, 4892–4900.
30. Kontny, U.; Franzen, S.; Behrends, U.; Buehrlen, M.; Christiansen, H.; Delecluse, H.; Eble, M.; Feuchtinger, T.; Gademann, G.; Grenzen, B.; et al. Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents—Recommendations of the GPOH-NPC Study Group. *Klin. Padiatr.* 2016, 228, 105–112.
31. Yao, J.-J.; Jin, Y.-N.; Lin, Y.-J.; Zhang, W.-J.; Marks, T.; Ryan, I.; Zhang, H.-Y.; Xia, L.-P. The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy. *Radiother. Oncol.* 2022; in press.
32. Mai, H.-Q.; Yang, J.-H.; Guo, S.-S.; Sun, X.-S.; Liu, L.-Z.; Yang, Z.-C.; Liu, L.; Liu, S.-L.; Li, X.Y.; Luo, D.-H.; et al. Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: A single-arm, phase II trial. *J. Clin. Oncol.* 2022, 40, 6002.
33. Kong, F.; Ying, H.; Du, C.; Huang, S.; Zhou, J.; Chen, J.; Sun, L.; Chen, X.; Hu, C. Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma. *Radiat. Oncol.* 2014, 9, 60.

34. Bakst, R.L.; Lee, N.; Pfister, D.G.; Zelefsky, M.J.; Hunt, M.A.; Kraus, D.H.; Wolden, S.L. Hypofractionated Dose-Painting Intensity Modulated Radiation Therapy With Chemotherapy for Nasopharyngeal Carcinoma: A Prospective Trial. *Int. J. Radiat. Oncol. Biol. Phys.* 2011, 80, 148–153.
35. Kwong, D.L.; Sham, J.S.; Leung, L.H.; Cheng, A.C.; Ng, W.; Kwong, P.W.; Lui, W.; Yau, C.; Wu, P.; Wei, W.; et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* 2006, 64, 374–381.
36. Saleh-Ebrahimi, L.; Zwicker, F.; Muentner, M.W.; Bischof, M.; Lindel, K.; Debus, J.; E Huber, P.; Roeder, F. Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer—A retrospective single center analysis. *Radiat. Oncol.* 2013, 8, 20.
37. Zhao, L.-N.; Zhou, B.; Shi, M.; Wang, J.-H.; Xiao, F.; Xu, M.; Luo, S.-Q.; Xue, Y.; Li, J.-P.; Tan, L.-N. Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in a non-endemic region of China. *Oral Oncol.* 2012, 48, 864–869.
38. Wang, J.; Zheng, J.; Tang, T.; Zhu, F.; Yao, Y.; Xu, J.; Wang, A.Z.; Zhang, L. A Randomized Pilot Trial Comparing Position Emission Tomography (PET)-Guided Dose Escalation Radiotherapy to Conventional Radiotherapy in Chemoradiotherapy Treatment of Locally Advanced Nasopharyngeal Carcinoma. *PLoS ONE* 2015, 10, e0124018.
39. Liu, F.; Xi, X.-P.; Wang, H.; Han, Y.-Q.; Xiao, F.; Hu, Y.; He, Q.; Zhang, L.; Xiao, Q.; Liu, L.; et al. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma. *Radiat. Oncol.* 2017, 12, 15.
40. Yan, D.-F.; Zhang, W.-B.; Ke, S.-B.; Zhao, F.; Yan, S.-X.; Wang, Q.-D.; Teng, L.-S. The prognostic value of pretreatment tumor apparent diffusion coefficient values in nasopharyngeal carcinoma. *BMC Cancer* 2017, 17, 678.
41. Fu, S.; Li, Y.; Han, Y.; Wang, H.; Chen, Y.; Yan, O.; He, Q.; Ma, H.; Liu, L.; Liu, F. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial. *Int. J. Radiat. Oncol. Biol. Phys.* 2022, 113, 101–113.
42. Ng, S.P.; Corry, J.; Ng, W.-T. The Janus Face in Defining the Optimal Radiation Dose for Nasopharyngeal Carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* 2022, 113, 114–116.
43. Mui, A.W.; Lee, A.W.; Lee, V.H.; Ng, W.; Vardhanabhuti, V.; Man, S.S.; Chua, D.T.; Law, S.C.; Guan, X. Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). *Magn. Reson. Imaging* 2021, 83, 50–56.
44. Sun, Y.; Yu, X.-L.; Luo, W.; Lee, A.W.; Wee, J.T.S.; Lee, N.; Zhou, G.-Q.; Tang, L.-L.; Tao, C.-J.; Guo, R.; et al. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. *Radiother. Oncol.* 2014, 110, 390–397.
45. Kam, M.K.; Leung, S.-F.; Zee, B.C.-Y.; Chau, R.M.; Suen, J.J.; Mo, F.; Lai, M.; Ho, R.; Cheung, K.-Y.; Yu, B.K.; et al. Prospective Randomized Study of Intensity-Modulated Radiotherapy on Salivary Gland Function in Early-Stage Nasopharyngeal Carcinoma Patients. *J. Clin. Oncol.* 2007, 25, 4873–4879.
46. Pow, E.H.; Kwong, D.L.; McMillan, A.S.; Wong, M.C.; Sham, J.S.; Leung, L.H.; Leung, W.K. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. *Int. J. Radiat. Oncol. Biol. Phys.* 2006, 66, 981–991.
47. Peng, G.; Wang, T.; Yang, K.-Y.; Zhang, S.; Zhang, T.; Li, Q.; Han, J.; Wu, G. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. *Radiother. Oncol.* 2012, 104, 286–293.
48. Bhandare, N.; Jackson, A.; Eisbruch, A.; Pan, C.C.; Flickinger, J.; Antonelli, P.; Mendenhall, W.M. Radiation Therapy and Hearing Loss. *Int. J. Radiat. Oncol. Biol. Phys.* 2010, 76, S50–S57.
49. Brodin, N.; Tomé, W.A. Revisiting the dose constraints for head and neck OARs in the current era of IMRT. *Oral Oncol.* 2018, 86, 8–18.
50. Gao, J.; Qian, T.-L.; Tao, C.-Z.; Zhang, Y.-H.; Zhou, Y.; Yang, J.; He, J.; Wang, R.; Zhou, P.-J. SmartArc-based volumetric modulated arc therapy can improve the middle ear, vestibule and cochlea sparing for locoregionally advanced nasopharyngeal carcinoma: A dosimetric comparison with step-and-shoot intensity-modulated radiotherapy. *Br. J. Radiol.* 2015, 88, 20150052.
51. Lamaj, E.; Vu, E.; van Timmeren, J.E.; Leonardi, C.; Marc, L.; Pytko, I.; Nuernberger, M.; Balermipas, P. Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma. *Radiat. Oncol.* 2021, 16, 64.

52. Zhang, C.; Liu, L.-X.; Li, W.-Z.; Liang, W.; Chen, Z.-H.; Huang, X.-H.; Qi, J.; Chen, X.-H.; Liang, J.-G.; Cao, X.-L. Cochlea sparing with a stratified scheme of dose limitation employed in intensity-modulated radiotherapy for nasopharyngeal carcinoma: A dosimetry study. *Med. Dosim.* 2019, 44, 226–232.
53. Lu, S.-H.; Cheng, J.C.-H.; Kuo, S.-H.; Lee, J.J.-S.; Chen, L.-H.; Wu, J.-K.; Chen, Y.-H.; Chen, W.-Y.; Wen, S.-Y.; Chong, F.-C.; et al. Volumetric modulated arc therapy for nasopharyngeal carcinoma: A dosimetric comparison with TomoTherapy and step-and-shoot IMRT. *Radiother. Oncol.* 2012, 104, 324–330.
54. Lee, T.-F.; Ting, H.-M.; Chao, P.-J.; Fang, F.-M. Dual Arc Volumetric-modulated Arc Radiotherapy (VMAT) of Nasopharyngeal Carcinomas: A Simultaneous Integrated Boost Treatment Plan Comparison with Intensity-modulated Radiotherapies and Single Arc VMAT. *Clin. Oncol.* 2012, 24, 196–207.
55. Delanian, S.; Lefaix, J.-L.; Pradat, P.-F. Radiation-induced neuropathy in cancer survivors. *Radiother. Oncol.* 2012, 105, 273–282.
56. Rong, X.; Tang, Y.; Chen, M.; Lu, K.; Peng, Y. Radiation-induced cranial neuropathy in patients with nasopharyngeal carcinoma. A follow-up study. *Strahlenther. Onkol.* 2012, 188, 282–286.
57. Chow, J.C.; Cheung, K.-M.; Au, K.-H.; Zee, B.C.-Y.; Lee, J.; Ngan, R.K.; Lee, A.W.; Yiu, H.H.; Li, K.W.; Leung, A.K.; et al. Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and dose–toxicity relationship. *Radiother. Oncol.* 2019, 138, 93–98.
58. Chow, J.C.; Lui, J.C.; Au, K.-H.; Cheung, K.-M.; Ngan, R.K.; Leung, A.K.; Li, K.W.; Chan, J.C.; Wong, K.-H.; Lee, F.K. Application of hypoglossal nerve constraint in definitive radiotherapy for nasopharyngeal carcinoma: A dosimetric feasibility study. *Med. Dosim.* 2020, 46, 39–44.

Retrieved from <https://encyclopedia.pub/entry/history/show/91872>